Maralixibat-to-Odevixibat Switch Linked to Pruritus Improvement in ALGS

A retrospective study presented at The Liver Meeting 2026 suggests that switching from maralixibat to odevixibat may improve pruritus in adolescents with Alagille syndrome. The findings indicate that patients intolerant to one IBAT inhibitor may still benefit from another.
Why it matters
This research provides clinical options for managing chronic, debilitating symptoms in pediatric patients with rare liver diseases.
Pruritus improved in 3 adolescents with Alagille syndrome (ALGS) after switching from maralixibat to odevixibat, according to preliminary findings from a retrospective chart review presented at The Liver Meeting 2026 in Denver. Gastrointestinal adverse events reported during odevixibat treatment were transient and resolved without discontinuation by the data cutoff.¹
Nadia Ovchinsky, MD, director of the Division of Pediatric Gastroenterology and Hepatology in the Department of Pediatrics at NYU Grossman School of Medicine, discussed the findings in an interview with HCP Live. She emphasized that intolerance or inadequate response to one ileal bile acid transporter (IBAT) inhibitor may not rule out benefit from another in selected patients.
The multicenter review in France and the US had enrolled 5 patients by March 25, 2026; this interim analysis focused on 3 adolescents. Eligible patients had genetically confirmed ALGS and received each medication for ≥4 weeks.¹
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in